Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (4,103)	$ (20,590)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization expense	1,073	66
Amortization of debt issuance costs	0	70
Loss on dissenting shareholders' liability	1,103	0
Loss (gain) on disposal of property, plant, and equipment	9	10
Share-based compensation	373	44
Impairment of operating lease right-of-use assets	56	0
Gain on lease settlement	(14)	0
Deferred income taxes	35	0
Provision for credit losses	2	0
Amortization of operating lease right-of-use assets	152	36
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	(18)	0
Materials and supplies	(339)	0
Prepaid expenses and other assets	(308)	(27)
Accounts payable, accrued expenses, and other liabilities	1,178	(627)
Operating lease liabilities	(152)	(37)
Income taxes receivable	0	31
Cash provided by (used in) operating activities from discontinued operations	(192)	22,059
Net cash (used in) provided by operating activities	(1,145)	1,035
Cash flows from investing activities:
Cash paid for acquisition of Amplex	(18,364)	0
Payments for property, plant, and equipment	(6,228)	0
Proceeds from the disposal of property, plant, and equipment	69	13
Net cash provided by investing activities from discontinued operations	39,006	35,440
Net cash provided by investing activities	14,483	35,427
Cash flows from financing activities:
Proceeds from RUS Loan	615	0
Proceeds from Bank Equipment Financing Loans	226	0
Repurchase of dissenting shares	(5,629)	0
Cash used in financing activities from discontinued operations	0	(29,100)
Net cash used in financing activities	(4,788)	(29,100)
Net increase in cash and cash equivalents	8,550	7,362
Cash, cash equivalents and restricted cash at beginning of period	18,982	454
Cash, cash equivalents and restricted cash at end of period	27,531	7,817
Total cash, cash equivalents and restricted cash at end of period	27,531	7,818
Reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the total amounts reported on the condensed consolidated statements of cash flows:
Cash and cash equivalents at beginning of period	18,982	454
Restricted cash included in Prepaid expenses and other assets at beginning of period	0	0
Total cash, cash equivalents and restricted cash at beginning of period	27,531	7,817
Cash and cash equivalents at end of period	27,132	7,818
Restricted cash included in Prepaid expenses and other assets at end of period	399	0
Total cash, cash equivalents and restricted cash at end of period	27,531	7,817
Supplemental disclosure of cash flow information:
Interest paid	0	975
Supplemental schedule of noncash investing and financing activities:
Purchase of property, plant, and equipment included in accounts payable	774	0
Conversion of term loan advances into additional equity of controlled entity (Amplex)	754
Additional investments in controlled entity (Amplex)	7,500	0
Redeemable noncontrolling interest redemption value in excess of carrying value deemed dividend	154	0
Transfer of finance receivables to repossessed assets	$ 0	$ 14,034